NuGene BioPharma acquires FDA-approved skin protectant cream SkinGuardian

NuGene BioPharma has acquired all intellectual property held by SkinGuardian, a FDA-approved (monographed) skin protectant, antiseptic, and moisturizing topical cream.

The company is a subsidiary of regenerative cosmeceutical and pharmaceutical products manufacturer NuGene International.

The acquisition covers the patent under which the SkinGuardian technology is protected, the company trademark, all formulas and derivatives under the patent, clinical trial data, and any and all other rights, title and interest in and to the SkinGuardian product.

As part of the transaction, SkinGuardian founder and owner Chris O’Brien will provide ongoing consultation to NuGene.

NuGene International CEO Ali Kharazmi said: "As stated previously, NuGene’s stem cell technologies and applications extend beyond the cosmeceutical and hair care market, the focus of NuGene International.

"We decided to form NuGene BioPharma in order to develop and market FDA-approved products that have pharmacological properties that can enhance the healing of wounds and skin conditions."

SkinGuardian claims to provide an antimicrobial composition that may be used to combat several microorganisms including bacteria, fungi, prions and viruses. It serves as an effective guard for damaged and/or undamaged skin, and as an effective guard against infections.

The antimicrobial composition of the cream has proved to be effective against viruses, and more specifically, enveloped and non-enveloped viruses.

"We see this FDA-approved topical cream as the foundation for a variety of topical treatments we will be developing that incorporate the use of stem cells to enhance healing.

"This is a prime example of the type of synergistic acquisitions we intend to make that will expand our range of opportunities while significantly reducing our time to market," Kharazmi added.